Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27163152 | 1.00 | CRBN (0.47) | CRBNARCDK9DDB1ALK | |
| SCHEMBL29976075 | 0.93 | CRBN (0.49) | CRBNARCDK9DDB1ALK | |
| SCHEMBL27161955 | 0.93 | CRBN (0.49) | CRBNARCDK9DDB1ALK | |
| SCHEMBL29802996 | 0.93 | CRBN (0.48) | CRBNARCDK9DDB1ALK | |
| SCHEMBL28795322 | 0.93 | CRBN (0.48) | CRBNARCDK9DDB1ALK | |
| SCHEMBL27162159 | 0.92 | CDK9 (0.47) | CRBNARCDK9DDB1ALK | |
| SCHEMBL29976308 | 0.92 | CDK9 (0.47) | CRBNARCDK9DDB1ALK | |
| SCHEMBL29976842 | 0.91 | CDK9 (0.49) | CRBNARCDK9DDB1ALK | |
| SCHEMBL29976262 | 0.91 | CRBN (0.47) | CRBNARCDK9DDB1ALK | |
| SCHEMBL27161991 | 0.91 | CRBN (0.47) | CRBNARCDK9DDB1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4332100-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2022228547-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | EGFR, BLK, CSNK1A1L | CRBN 2155/4885AR 602/4885CDK9 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.